Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 1
2002 1
2003 5
2004 4
2005 11
2006 9
2007 10
2008 5
2009 2
2010 1
2011 9
2012 10
2013 12
2014 12
2015 6
2016 4
2017 4
2018 9
2019 6
2020 11
2021 14
2022 15
2023 12
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Ytterberg SR, et al. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
Characteristics of patients with late recurrence endometrial cancer.
Çakır İ, Gülseren V, Özdemir İA, Abacı H, Talu ECK, Çakır ZE, Ata C, Kuru O, Gökçü M, Sancı M, Güngördük K. Çakır İ, et al. Among authors: kuru o. J Cancer Res Ther. 2024 Jan 1;20(1):232-237. doi: 10.4103/jcrt.jcrt_888_22. Epub 2023 Apr 8. J Cancer Res Ther. 2024. PMID: 38554326 Free article. Review.
The ocular findings related to oral bisphosphonate use.
Atar S, Yurttaser SO, Demirhan E, Er G, Kuru Ö. Atar S, et al. Among authors: kuru o. Arch Soc Esp Oftalmol (Engl Ed). 2022 Sep;97(9):497-503. doi: 10.1016/j.oftale.2022.06.006. Epub 2022 Jul 2. Arch Soc Esp Oftalmol (Engl Ed). 2022. PMID: 35787381
Analysis of vanishing endometrial cancer by pathological types.
Görgülü G, Doğan Özdaş E, Özdaş E, Sayhan S, Kuru O, Gökçü M, Sancı M. Görgülü G, et al. Among authors: kuru o. J Obstet Gynaecol Res. 2022 Aug;48(8):2175-2179. doi: 10.1111/jog.15294. Epub 2022 Jun 9. J Obstet Gynaecol Res. 2022. PMID: 35686358
Adnexal masses in patients with colorectal cancer.
Akgor U, Kuru O, Soyak B, Gunes AC, Uyanık E, Gultekin M, Ozgul N, Salman C. Akgor U, et al. Among authors: kuru o. J Gynecol Obstet Hum Reprod. 2021 May;50(5):101898. doi: 10.1016/j.jogoh.2020.101898. Epub 2020 Aug 19. J Gynecol Obstet Hum Reprod. 2021. PMID: 32827838
149 results